Contrasting TransMedics Group (NASDAQ:TMDX) and Paradigm Medical Industries (OTCMKTS:PDMI)

TransMedics Group (NASDAQ:TMDX) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Valuation and Earnings

This table compares TransMedics Group and Paradigm Medical Industries”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49 million	6.46	$190.29 million	$4.90	23.27
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

TransMedics Group has higher revenue and earnings than Paradigm Medical Industries.

Profitability

This table compares TransMedics Group and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	31.43%	30.17%	11.39%
Paradigm Medical Industries	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for TransMedics Group and Paradigm Medical Industries, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	5	7	0	2.58
Paradigm Medical Industries	0	0	0	0	0.00

TransMedics Group currently has a consensus price target of $152.33, suggesting a potential upside of 33.63%. Given TransMedics Group’s stronger consensus rating and higher possible upside, equities research analysts plainly believe TransMedics Group is more favorable than Paradigm Medical Industries.

Insider & Institutional Ownership

99.7% of TransMedics Group shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Paradigm Medical Industries on 8 of the 9 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.